Document is current
Any future updates will be listed below
-
Authors
de Cates, Angharad N. https://orcid.org/0000-0001-7848-1295
Wright, Lucy C.
Martens, Marieke A. G.
Gibson, Daisy
Türkmen, Cagdas
Filippini, Nicola
Cowen, Philip J. https://orcid.org/0000-0001-5518-6138
Harmer, Catherine J. https://orcid.org/0000-0002-1609-8335
Murphy, Susannah E. https://orcid.org/0000-0001-8995-2099
-
Funding
Funding for this research was provided by:
Wellcome Trust (216430/Z/19/Z, 203139/Z/16/Z, 203139/Z/16/Z, 203139/Z/16/Z, 203139/Z/16/Z, 203139/Z/16/Z)
- License Information
-
More Information
Article History
Received: 9 March 2021
Revised: 4 August 2021
Accepted: 16 August 2021
First Online: 4 October 2021
Competing interests
: CJH has received consultancy fees from P1vital Ltd., Janssen Pharmaceuticals, Sage Therapeutics, Pfizer, Zogenix, Compass Pathways, and Lundbeck. SEM has received consultancy fees from Zogenix, Sumitomo Dainippon Pharma, P1vital Ltd., and Janssen Pharmaceuticals. CJH and SEM hold grant income from Zogenix, UCB Pharma, and Janssen Pharmaceuticals. CJH, SEM, and PJC hold grant income from a collaborative research project with Pfizer. ANdeC has received a travel grant from the Royal College of Psychiatrists/Gatsby Foundation alongside support from Wellcome. MM is and NFwas at the time of the study funded by the NIHR. LCW, DG, and CT have no conflicts of interest to declare.
